References:
1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and
national disease burden estimates of acute lower respiratory infections
due to respiratory syncytial virus in young children in 2015: a
systematic review and modelling study. Lancet. 2017 ;
390(10098):946–958.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower
respiratory infections due to respiratory syncytial virus in young
children: a systematic review and meta-analysis. Lancet. 2010 ;
375(9725):1545–1555.
3. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated
with influenza and respiratory syncytial virus in the United States,
1993-2008. Clin Infect Dis. 2012 ; 54(10):1427–1436.
4. Kramer R, Duclos A, VRS study group in Lyon, Lina B, Casalegno J-S.
Cost and burden of RSV related hospitalisation from 2012 to 2017 in the
first year of life in Lyon, France. Vaccine. 2018 ;
36(45):6591–6593.
5. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory
syncytial virus-associated hospitalizations among infants and young
children in the United States, 1997-2006. Pediatr Infect Dis J.2012 ; 31(1):5–9.
6. Simões EAF, Bont L, Manzoni P, et al. Past, Present and Future
Approaches to the Prevention and Treatment of Respiratory Syncytial
Virus Infection in Children. Infect Dis Ther. 2018 ;
7(1):87–120.
7. Karron RA. Preventing respiratory syncytial virus (RSV) disease in
children. Science. 2021 ; 372(6543):686–687.
8. Graham BS. Vaccine development for respiratory syncytial virus. Curr
Opin Virol. 2017 ; 23:107–112.
9. Bakker SE, Duquerroy S, Galloux M, et al. The respiratory syncytial
virus nucleoprotein–RNA complex forms a left-handed helical
nucleocapsid. J Gen Virol. 2013 ; 94(Pt 8):1734–1738.
10. Collins PL, Fearns R, Graham BS. Respiratory syncytial virus:
virology, reverse genetics, and pathogenesis of disease. Curr Top
Microbiol Immunol. 2013 ; 372:3–38.
11. Abarca K, Rey-Jurado E, Muñoz-Durango N, et al. Safety and
immunogenicity evaluation of recombinant BCG vaccine against respiratory
syncytial virus in a randomized, double-blind, placebo-controlled phase
I clinical trial. EClinicalMedicine. 2020 ; 27:100517.
12. Green CA, Scarselli E, Voysey M, et al. Safety and immunogenicity of
novel respiratory syncytial virus (RSV) vaccines based on the RSV viral
proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA
(MVA-RSV); protocol for an open-label, dose-escalation, single-centre,
phase 1 clinical trial in healthy adults. BMJ Open. 2015 ;
5(10):e008748.
13. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV
Vaccine Consultation Expert Group. WHO consultation on Respiratory
Syncytial Virus Vaccine Development Report from a World Health
Organization Meeting held on 23-24 March 2015. Vaccine. 2016 ;
34(2):190–197.
14. Jones CE, Calvert A, Le Doare K. Vaccination in Pregnancy-Recent
Developments. Pediatr Infect Dis J. 2018 ; 37(2):191–193.
15. Wilcox CR, Holder B, Jones CE. Factors Affecting the FcRn-Mediated
Transplacental Transfer of Antibodies and Implications for Vaccination
in Pregnancy. Frontiers in Immunology. 2017 ; 8:1294.
16. Eick A, Karron R, Shaw J, et al. The role of neutralizing antibodies
in protection of American Indian infants against respiratory syncytial
virus disease. Pediatr Infect Dis J. 2008 ; 27(3):207–212.
17. Stensballe LG, Ravn H, Kristensen K, et al. Respiratory syncytial
virus neutralizing antibodies in cord blood, respiratory syncytial virus
hospitalization, and recurrent wheeze. J Allergy Clin Immunol.2009 ; 123(2):398–403.
18. Buchwald AG, Graham BS, Traore A, et al. RSV neutralizing antibodies
at birth predict protection from RSV illness in infants in the first
three months of life. Clin Infect Dis. 2020 ; ciaa648.
19. Bulkow LR, Singleton RJ, Karron RA, Harrison LH, Alaska RSV Study
Group. Risk factors for severe respiratory syncytial virus infection
among Alaska native children. Pediatrics. 2002 ;
109(2):210–216.
20. Nyiro JU, Sande CJ, Mutunga M, et al. Absence of Association between
Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus
(RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya.
PLoS One. 2016 ; 11(11):e0166706.
21. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional,
and worldwide estimates of preterm birth rates in the year 2010 with
time trends since 1990 for selected countries: a systematic analysis and
implications. Lancet. 2012 ; 379(9832):2162–2172.
22. Kramer MS, Papageorghiou A, Culhane J, et al. Challenges in defining
and classifying the preterm birth syndrome. Am J Obstet Gynecol.2012 ; 206(2):108–112.
23. Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS. Meeting
report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine
development, Geneva, 25-26 April 2016. Vaccine. 2019 ;
37(50):7355–7362.
24. Capella C, Chaiwatpongsakorn S, Gorrell E, et al. Prefusion F,
Postfusion F, G Antibodies, and Disease Severity in Infants and Young
Children With Acute Respiratory Syncytial Virus Infection. J Infect Dis.2017 ; 216(11):1398–1406.
25. Buchwald AG, Graham BS, Traore A, et al. RSV neutralizing antibodies
at birth predict protection from RSV illness in infants in the first
three months of life. Clin Infect Dis. 2020 ; ciaa248.
26. Gaymard A, Bouscambert-Duchamp M, Pichon M, et al. Genetic
characterization of respiratory syncytial virus highlights a new BA
genotype and emergence of the ON1 genotype in Lyon, France, between 2010
and 2014. J Clin Virol. 2018 ; 102:12–18.
27. Roux X, Dubuquoy C, Durand G, et al. Sub-nucleocapsid nanoparticles:
a nasal vaccine against respiratory syncytial virus. PLoS One.2008 ; 3(3):e1766.
28. Linder N, Ohel G. In utero vaccination. Clin Perinatol.1994 ; 21(3):663–674.
29. Mammas IN, Drysdale SB, Rath B, et al. Update on current views and
advances on RSV infection (Review). Int J Mol Med. 2020 ;
46(2):509–520.
30. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of
maternofetal transport of immunoglobulins during human pregnancy. Am J
Reprod Immunol. 1996 ; 36(5):248–255.
31. Homaira N, Mallitt K-A, Oei J-L, et al. Risk factors associated with
RSV hospitalisation in the first 2 years of life, among different
subgroups of children in NSW: a whole-of-population-based cohort study.
BMJ Open. 2016 ; 6(6):e011398.
32. Bont L, Checchia PA, Fauroux B, et al. Defining the Epidemiology and
Burden of Severe Respiratory Syncytial Virus Infection Among Infants and
Children in Western Countries. Infect Dis Ther. 2016 ;
5(3):271–298.
33. Aikphaibul P, Theerawit T, Sophonphan J, Wacharachaisurapol N,
Jitrungruengnij N, Puthanakit T. Risk factors of severe hospitalized
respiratory syncytial virus infection in tertiary care center in
Thailand. Influenza Other Respir Viruses. 2021 ; 15(1):64–71.